<DOC>
	<DOCNO>NCT02312037</DOCNO>
	<brief_summary>An expanded access/compassionate use protocol allow access Mylotarg relapsed/refractory AML CD33 positive patient USA . Contact : B1761026 @ iconplc.com</brief_summary>
	<brief_title>Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy</brief_title>
	<detailed_description>Contact : B1761026 @ iconplc.com</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Confirmed diagnosis relapsed/refractory AML ( define &gt; =5 % marrow blast morphology ) , include MDS , persist rise blast comparable satisfactory alternative therapy available . If bone marrow &lt; 5 % blast morphology patient evidence relapse extramedullary disease progression . In select case present conversion MRD negative positive , treatment GO may allow alternative treatment feasible . OR Confirmed diagnosis relapse refractory APL persist rise leukemic burden ( either morphology , cytogenetic analysis molecular technique ) , comparable satisfactory alternative therapy available . Documentation malignant cell express CD33 4 ) Age &gt; =3 month 5 ) Adequate nonhematologic organ function Untreated AML MDS AML MDS complete remission . Patients known history VOD/SOS . Patients know hypersensitivity Mylotarg part : hP67.6 antibody , calicheamicin derivative ingredient . Participation study involve investigational drug ( ) ( Phases 14 ) study participation .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Relapsed CD33 AML</keyword>
	<keyword>Refractory CD33 AML</keyword>
	<keyword>Relapsed CD33 APL</keyword>
	<keyword>Refractory CD33 APL</keyword>
	<keyword>Relapsed CD33 MDS</keyword>
	<keyword>Refractory CD33 MDS</keyword>
</DOC>